Molecular Neurobiology and Promising New Treatment in Depression

The limited effects of currently available antidepressants are becoming an urgent issue in depression research. It takes a long time to determine treatment effects, and the overall remission rate is low. Although we expect the development of non-monoamine antidepressants in the near future, efforts...

Full description

Bibliographic Details
Main Authors: Sang Won Jeon, Yong-Ku Kim
Format: Article
Language:English
Published: MDPI AG 2016-03-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/17/3/381
id doaj-1fe4fcb3be5444539bf84beae24a6488
record_format Article
spelling doaj-1fe4fcb3be5444539bf84beae24a64882020-11-24T22:18:45ZengMDPI AGInternational Journal of Molecular Sciences1422-00672016-03-0117338110.3390/ijms17030381ijms17030381Molecular Neurobiology and Promising New Treatment in DepressionSang Won Jeon0Yong-Ku Kim1Department of Psychiatry, College of Medicine, Korea University, Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Seoul 15355, KoreaDepartment of Psychiatry, College of Medicine, Korea University, Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Seoul 15355, KoreaThe limited effects of currently available antidepressants are becoming an urgent issue in depression research. It takes a long time to determine treatment effects, and the overall remission rate is low. Although we expect the development of non-monoamine antidepressants in the near future, efforts in this regard over the past several decades have not yet been compensated. Thus, researchers and clinicians should clarify the neurobiological mechanisms of integrated modulators that regulate changes in genes, cells, the brain, and behaviors associated with depression. In this study, we review molecular neurobiological theories and new treatments for depression. Beyond neuroanatomy and monoamine theory, we discuss cells and molecules, neural plasticity, neurotrophisms, endocrine mechanisms, immunological mechanisms, genetics, circadian rhythms, and metabolic regulation in depression. In addition, we introduce the possibility of new antidepressant drug development using protein translation signaling (mTOR) pathways.http://www.mdpi.com/1422-0067/17/3/381depressionneurobiologyantidepressantneural plasticityBDNFendocrineimmunegenemTOR
collection DOAJ
language English
format Article
sources DOAJ
author Sang Won Jeon
Yong-Ku Kim
spellingShingle Sang Won Jeon
Yong-Ku Kim
Molecular Neurobiology and Promising New Treatment in Depression
International Journal of Molecular Sciences
depression
neurobiology
antidepressant
neural plasticity
BDNF
endocrine
immune
gene
mTOR
author_facet Sang Won Jeon
Yong-Ku Kim
author_sort Sang Won Jeon
title Molecular Neurobiology and Promising New Treatment in Depression
title_short Molecular Neurobiology and Promising New Treatment in Depression
title_full Molecular Neurobiology and Promising New Treatment in Depression
title_fullStr Molecular Neurobiology and Promising New Treatment in Depression
title_full_unstemmed Molecular Neurobiology and Promising New Treatment in Depression
title_sort molecular neurobiology and promising new treatment in depression
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2016-03-01
description The limited effects of currently available antidepressants are becoming an urgent issue in depression research. It takes a long time to determine treatment effects, and the overall remission rate is low. Although we expect the development of non-monoamine antidepressants in the near future, efforts in this regard over the past several decades have not yet been compensated. Thus, researchers and clinicians should clarify the neurobiological mechanisms of integrated modulators that regulate changes in genes, cells, the brain, and behaviors associated with depression. In this study, we review molecular neurobiological theories and new treatments for depression. Beyond neuroanatomy and monoamine theory, we discuss cells and molecules, neural plasticity, neurotrophisms, endocrine mechanisms, immunological mechanisms, genetics, circadian rhythms, and metabolic regulation in depression. In addition, we introduce the possibility of new antidepressant drug development using protein translation signaling (mTOR) pathways.
topic depression
neurobiology
antidepressant
neural plasticity
BDNF
endocrine
immune
gene
mTOR
url http://www.mdpi.com/1422-0067/17/3/381
work_keys_str_mv AT sangwonjeon molecularneurobiologyandpromisingnewtreatmentindepression
AT yongkukim molecularneurobiologyandpromisingnewtreatmentindepression
_version_ 1725781843734691840